Pharmagesic financials: $4.9M loss, $82M deficit; Dogwood provides $19.5M funding

Dogwood Therapeutics, Inc.

Pharmagesic (Holdings) Inc. (acquired Oct 7) had $4.9M net loss in 2023; no revenue; R&D costs $3.9M.
As of Dec 2023, stockholders' deficit was $78.7M, accumulated deficit $82.0M; total liabilities $65.1M.
Post-Dec 2023, $63.4M due to fellow subsidiaries settled; $36.0M preferred shares exchanged for common.
Dogwood secured $19.5M loan from CK Life Sciences to fund Pharmagesic operations through early 2026.
Halneuron (tetrodotoxin) is the lead candidate for chemotherapy-induced neuropathic pain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.